Efficacy of Baricitinib in Patients With Various Degrees of Alopecia Areata Severity: Results From Brave-AA1 and Brave-AA2
September 2022
in “Journal of The American Academy of Dermatology”
TLDR Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
The document presents the results of two phase 3 randomized, double-blinded, placebo-controlled trials (BRAVE-AA1 with 654 participants and BRAVE-AA2 with 546 participants) that evaluated the efficacy of Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, in adult patients with varying degrees of alopecia areata (AA) severity. The severity was measured using the Severity of Alopecia Tool (SALT) score. The primary efficacy endpoint was the proportions of patients achieving a SALT score ≤20 at week 36. The results showed that both 2mg and 4mg doses of Baricitinib were significantly superior to placebo in achieving hair regrowth (SALT ≤20) across all severity subgroups at week 36. Specifically, for severe AA, 32.7% of patients on 2mg and 47.6% on 4mg achieved this, compared to 7.8% on placebo. For very severe AA, the figures were 9.8% and 21.3% versus 0.6%, and for alopecia universalis, they were 19.6% and 27.7% versus 2.9%.
View this study on jaad.org →
Related
research Twenty nail dystrophy with alopecia areata in an atopic child
A child with rough nails also had hair loss and allergies.
research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.